Sign inJoin waitlistJoin the waitlist

Scott Kopetz

GGR Co-Leader · University of Texas M D Anderson Cancer Center

Credentials: · · · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
Gastrointestinal Medical Oncology Department · University of Texas M D Anderson Cancer Center
Present
Department of Gastrointestinal Medical Oncology · University of Texas M D Anderson Cancer Center
Present

Medical Oncology
University of Texas M D Anderson Cancer Center
2004–2006
Internal Medicine
Duke University Hospital
2001–2004
Johns Hopkins School of Medicine
1997–2001
Vanderbilt University
1993–1997

Research

The consensus molecular subtypes of colorectal cancer
Nature Medicine · 2015 · 4,083 citations
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
The Lancet Oncology · 2017 · 2,298 citations
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2018 · 1,662 citations

Michael Overman
133 papers · 8 as a fellow
Van Morris
74 papers · 8 as a fellow
Kanwal Raghav
72 papers
Cathy Eng
62 papers
Dipen Maru
62 papers
Arvind Dasari
53 papers
Robert Wolff
50 papers
Jean-Nicolas Vauthey
48 papers
Funda Meric-Bernstam
39 papers
Bryan Kee
37 papers
Christine Parseghian
34 papers · 7 as a fellow
David Hong
31 papers

Grants

The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $317.3K · University of Tx Md Anderson Can Ctr
1996–2031
Paul Calabresi Clinical Oncology Award
National Cancer Institute · K12
Contact PI · $3.2M · University of Tx Md Anderson Can Ctr
2000–2027
Overcoming Adaptive Feedback Resistance to KRAS Inhibition in Colorectal Cancer
National Cancer Institute · R01
PI · $3.5M · Massachusetts General Hospital
2022–2027
Mdacc-Predict
National Cancer Institute · U24
PI · $2M · University of Tx Md Anderson Can Ctr
2020–2025

Clinical trials

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
Principal investigator · Not yet recruiting · Early phase 1
M.D. Anderson Cancer Center
2026–2029
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Principal investigator · Completed
Alaunos Therapeutics
2023–2025
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Principal investigator · Terminated · Phase 1, Phase 2
Alaunos Therapeutics
2022–2023
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Principal investigator · Completed · Phase 2
Academic and Community Cancer Research United
2019–2024